{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:41Z","timestamp":1789621481169,"version":"build-2803163510"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2026.1925611","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:44:56Z","timestamp":1789620296000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Commentary: Recombinant Mycobacterium tuberculosis fusion protein for diagnosis of Mycobacterium tuberculosis infection: a short-term economic evaluation"],"prefix":"10.3389","volume":"14","author":[{"given":"Chaoyuan","family":"Ma","sequence":"first","affiliation":[{"name":"Hualan Biological Engineering Inc.","place":["Xinxiang, China"]},{"name":"Hualan Biological Vaccine Inc.","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Hualan Biological Vaccine Inc.","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1105857","DOI":"10.3389\/fpubh.2023.1105857","article-title":"Recombinant Mycobacterium tuberculosis fusion protein for diagnosis of Mycobacterium tuberculosis infection: a short-term economic evaluation","volume":"11","author":"Liu","year":"2023","journal-title":"Front Public Health."},{"key":"B2","unstructured":"Zhifei\n              Longcom Biologic Pharmacy Co\n            \n          \n          Instruction of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC)\n          \n          2020"},{"key":"B3","unstructured":"Ltd\n          \n          \n            \n              Beijing\n              Simcere Sanroad Biologicals Co\n            \n          \n          Instruction of Tuberculin Purified Protein Derivative (TB-PPD)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3760\/cma.j.issn.0253-2727.2019.01.010","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis","volume":"22","author":"Krutikov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1161526","DOI":"10.3389\/fphar.2023.1161526","article-title":"Long-term economic evaluation of the recombinant Mycobacterium tuberculosis fusion protein (EC) test for the diagnosis of Mycobacterium tuberculosis infection","volume":"14","author":"Diao","year":"2023","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1696952","DOI":"10.3389\/fpubh.2025.1696952","article-title":"Cost-effectiveness analysis of tuberculosis screening in diabetic patients in China: a decision-analytic Markov model","volume":"13","author":"Song","year":"2026","journal-title":"Front Public Health"},{"key":"B8","unstructured":"Geneva\n          World Health Organization\n          Rapid Communication: TB Antigen-Based Skin Tests for the Diagnosis of TB Infection.\n          \n          2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1925611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:45:22Z","timestamp":1789620322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1925611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":9,"alternative-id":["10.3389\/fpubh.2026.1925611"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1925611","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1925611"}}